Keyword: dupilumab

Regeneron

4. Leonard “Len” Schleifer

Regeneron's Praluent lagged far behind sales expectations, and it lost a patent trial. Company shares began to slide in late 2016, and that’s why Len Schleifer’s pay declined in 2016.